The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | -1.74% | -8.13% | -8.87% |
May. 09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-8.87% | 241M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |